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Peter B. Schiff 1, J. Keith DeWyngaert1 and Stella C. Lymberis1*
1 Department of Radiation Oncology, NYU Langone Medical Center, NYU Perlmutter Cancer Center, New York, NY, USA,
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Introduction: Evaluate use of novel multi-channel applicator (MC) Capri™ to improve
vaginal disease coverage achievable by single-channel applicator (SC) and comparable
to Syed plan simulation.
Materials and methods: Twenty-eight plans were evaluated from four patients with
primary or recurrent gynecologic cancer in the vagina. Each received whole pelvis
radiation, followed by three weekly treatments using HDR brachytherapy with a 13-
channel MC. Upper vagina was treated to 5mm depth to 1500 cGy/3 fractions with a
simultaneous integrated boost totaling 2100 cGy/3 fractions to tumor. Modeling of SC
and Syed plans was performed using MC scans for each patient. Dosimetry for MC and
SC plans was evaluated for PTV700 cGy coverage, maximum dose to 2 cm3 to bladder,
rectum, as well as mucosal surface points. Dosimetry for Syed plans was calculated for
PTV700 cGy coverage. Patients were followed for treatment response and toxicity.
Results: Dosimetric analysis between MC and SC plans demonstrated increased tumor
coverage (PTV700 cGy), with decreased rectal, bladder, and contralateral vaginal mucosa
dose in favor of MC. These differences were significant (p<0.05). Comparison of MC and
Syed plans demonstrated increased tumor coverage in favor of Syed plans which were
not significant (p=0.71). Patients treated with MC had no cancer recurrence or grade
3 toxicity.
Conclusion: Use of MC was efficacious and safe, providing superior coverage of tumor
volumes 1 cm depth compared to SC and comparable to Syed implant. MC avoids
excess dose to surrounding organs compared to SC, and potentially less morbidity than
Syed implants. For tumors extending 1 cm depth, use of MC represents an alternative
to an interstitial implant.
Keywords: multi-channel vaginal applicator, interstitial implant, single-channel applicator, toxicity
Abbreviations:MC, multi-channel applicator; OAR, organs at risk; PTV500 cGy, planning target volume to receive 500 cGy;
PTV700 cGy, planning target volume to receive 700 cGy; SC, single-channel applicator; SIB, simultaneous integrated
boost.
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Introduction
Patients with recurrent endometrial cancer following hysterec-
tomy or primary vaginal cancer with disease limited to the pelvis
are often treated with multi-modality treatment with curative
intent. One option includes the use of whole pelvis radiation
followed by either a tumor directed boost using brachytherapy or
focused external beam radiation to disease in the vagina (1–6).
The type of brachytherapy used is dependent on depth and size
of tumor within the vaginal vault. Non-bulky disease, 5mm in
thickness or depth, can be treated with intracavitary brachyther-
apy, while bulky disease, >5mm in thickness or disease beyond
the vaginal surface, is more suitable for an interstitial approach
(3). Patients presenting with extensive vaginal or paravaginal
disease, disease with bulky parametrial extension, disease in the
vaginal apex, or pelvic anatomy resulting in suboptimal dose
distribution using intracavitary brachytherapy may also benefit
from treatment using an interstitial implant (7–10).
Although non-bulky disease in the vagina or vaginal cuff can be
treated with a rigid intracavitary single-channel vaginal cylinder,
there is no ability to sculpt dose away from organs at risk (OARs),
such as the bladder and rectum.Multi-channel applicators (MCs),
however, can allow for preferential treatment of lateralized disease
while decreasing dose delivered to OARs through a modulation
of dwell times in various positions along the channels (11). In
addition, dose gradient in the radial direction allows steep dose
falloff as source channels are placed close to the tumor volume
compared to a single-channel applicator (SC) (12). Furthermore,
with preferential dwell times, sparing of OARs distant to the lesion
being treated can be spared due to the radial dose inhomogeneity
achieved by strategic channel loading.
Despite a study demonstrating superior dosimetry between
MC and SC with respect to tumor coverage and decreased dose
to OARs, SC are more commonly used due to decreased cost,
increased ease of use, and availability (11, 13). One recent dosi-
metric study compared use of a MC with that of a SC and
demonstrated similar tumor coverage, however with statistically
significant dose reduction to bladder and rectum in favor of the
MC when compared to a SC at 5mm prescription depth (13).
The first clinical implementation of the newly FDA approved
Capri™ multi-channel applicator in five patients demonstrated
reduced rectal dose and suggested usefulness to cover extensive
vaginal disease (14). In our initial experience, we report the use of
the Capri™ multi-channel applicator in the treatment of vaginal
disease originating from primary vaginal or endometrial cancer
(Figure 1). Compared with the published experience using the
Miami Multichannel Applicator where a plan was generated prior
to the first treatment and used for all fractions, patients underwent
real-time planning prior to all three fractions (15). In addition, we
compared dosimetry of MC to a SC and an interstitial implant.
The goals of our study are first to compare dose distributions rep-
resentative of MC, SC, and interstitial implants under conditions
where tumor extends up to 1 cm depth and second to evaluate
our clinical experience using the MC with respect to efficacy and
toxicity of treatment. Dosimetry was compared between a MC
and a SC with respect to tumor coverage and dose to OARs, and
between a MC and an interstitial implant (Syed) with respect to
tumor coverage.
FIGURE 1 |Multi channel (Capri) applicator inflated and deflated with
display of axial cross-section.
Materials and Methods
Four patients with diagnosis of primary vaginal cancer (n= 2) or
recurrent endometrial cancer (n= 2) with disease limited to the
vagina were treated with a MC between December 2012 and June
2013. The MC used in this study was the Capri™(Varian Medical
Systems, Palo Alto, CA, USA) applicator, a single use, flexible,
inflatable (2011 US Food and Drug Administration-cleared) vagi-
nal applicator with 13 channels (Figure 1). The applicator consists
of a central channel, an inner array of six channels, and an outer
array of six channels. Each lumen is impregnated with barium
sulfate in addition to internal markers allowing for identification
of each catheter. The applicator has a deflated insertion diameter
of 29mm, but is inflated using saline to conform to a patient’s
pelvic anatomy.
Prior to treatment withMC, all patients underwent appropriate
staging evaluation with pelvic examination, biopsy, and imag-
ing, including computerized tomography (CT) and/or magnetic
resonance imaging (MRI) of the abdomen and pelvis prior to
consultation. During pelvic examination, patients had up to two
fiducial markers placed into the submucosa near the site of disease
in the vagina. All fiducial markers were placed by a single sur-
geon. Following fiducial marker placement, patients were treated
with whole pelvis radiation to a dose of 4500 cGy in 25 fractions
using a four-field technique with photons. Following whole pelvis
treatment, patients underwent pelvic examination to determine
response of disease in the vagina. All four patients presented with
tumor >5mm, but 10mm in depth and size at the time of
pelvic re-examination, andwere selected to be treatedwith theMC
instead of a SC or Syed.
Patients were instructed to drink 16 ounces of water prior to
insertion of the MC. A foley catheter was not placed prior to
insertion ofMC. Local anesthetic gel and lubricant gel was utilized
prior to inserting the deflated MC into the patient’s vagina. Fol-
lowing insertion, the MCwas inflated to the largest diameter with
saline to the shape and diameter of the patient’s vaginal anatomy
to prevent displacement of the applicator, to reduce air gaps (16),
to reduce vaginal mucosal dose, thereby achieving optimal dose
distribution. A 1.25mm axial CT slice thickness CT scan was
generated at 120 kVp using a LightSpeed RT 16 CT Simulator
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(GEHealthcare,Waukesha,WI, USA). The CT images were trans-
ferred to the Eclipse treatment planning system (Varian, Palo Alto,
CA, USA). One physician contoured the bladder, rectum, and the
gross tumor volume (GTV), representing vaginal tumor demar-
cated by fiducial markers. Rectum was contoured from the recto-
sigmoid junction superiorly to the ischial tuberosity inferiorly,
and the entire bladder was contoured. Physicists then contoured
the MC, the PTV500 cGy (planning target volume to receive
500 cGy) and the PTV700 cGy (planning target volume to receive
700 cGy). The PTV500 cGy was created with a 5mm expansion of
theMC and a 3mm expansion of the GTV combined as a Boolean
structure, while the PTV700 cGy was defined as equivalent to the
GTV. OARs (bladder and rectum) were not cropped too closely
to mimic traditional cylinder planning and to account for bladder
and rectal filling changes between the time of CT and the time of
treatment plan delivery.
Plans were created with the MC in place, and each patient
received threeweekly insertions of Iridium-192 high dose rateMC
treatment (Figures 2B and 3C). A CT simulation was performed
for each fraction (weekly insertion), and a separate plan was
created from the CT scan. A total dose of 15Gy was delivered
to the upper two-thirds of the vagina, prescribed to a depth of
5mm in three weekly fractions with a simultaneous integrated
boost (SIB) of 21Gy to the PTV700 cGy in three weekly fractions,
prescribed to a depth up to 10mm from the applicator surface.
Varian Brachyvision was used for treatment planning with source
dwell positions separated by 5mm (Varian, Palo Alto, CA, USA).
Volumetric optimization was used, setting appropriate dose con-
straints to deliver the prescribed doses to the target volumes.
Contoured OARs were utilized to help conform the dose to
target volumes. Post-optimization, each plan was evaluated and
modified to eliminate the use of catheters with very few, low
dwell time source positions. Outer catheter use was limited to
the coverage of the PTV700 cGy when possible. Dosimetry for
MC plans was evaluated for PTV coverage, maximum D2cm3 to
bladder and rectum, as well as vaginal mucosal surface points
ipsilateral and contralateral to PTV700 cGy. An α/β= 3 was
used to determine cumulative biological effective dose BED3 (Gy)
of whole pelvis radiation and three weekly insertions of MC to
the normal structures bladder, rectum, and including proximal
vagina. An EQD2 (converting the BED3 values to equivalent total
doses delivered in 2Gy fractions) was also calculated for dose to
vagina. Following treatment with the MC, patients were seen in
follow-up at 1, 3, 6months, and yearly thereafter.
Modeling of SC plans was performed using existing initial
planning CT data sets for all four patients treated with the MC
(Figures 2 and 3). The SC plans were modeled by loading the
single central catheter of the MC. SC plans were optimized for
PTV700 cGy coverage, maximum D2cm3 to bladder and rectum
as well as mucosal surface points. In order to ensure fair compar-
ison, the D95 of PTV500 cGy was set equivalent for each of the
MC and SC plans. Syed plans were also generated using existing
initial planning CT data sets for all four patients treated with
the MC (Figure 3), and optimized for PTV700 cGy coverage.
FIGURE 2 | Example of single-channel (A) and multi-channel (B) dosimetric plans in the coronal plane [yellow=5Gy isodose line, blue=7Gy isodose
line, Red=PTV5Gy, Teal =PTV7Gy (GTV)].
FIGURE 3 | Example of dosimetric plans [Syed (A), single-channel (B), multi-channel (C)] for a patient with recurrent endometrial cancer in the axial
plane. Multi channel plan (C) was created using 13-channel applicator. SC (B) and Syed (A) plans modeled using pre-existing MC plan. Location of catheters loaded
for each of the plans is depicted in green.
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TABLE 1 | Comparison of dosimetry to target (PTV) and dose to organs at risk between multi-channel and single-channel applicator.
PTV700 cGy
D99 (cGy)
PTV700 cGy
D95 (cGy)
PTV500 cGy
D99 (cGy)
PTV500 cGy
D95 (cGy)
D2cc bladder
(cGy)
D2cc rectum
(cGy)
Contralateral
mucosa (cGy)
Ipsilateral
mucosa (cGy)
MC 711.6 749.3 484.0 523.3 576.4 622.8 882.0 1448.0
SC 643.2 674.1 476.8 524.2 707.1 706.0 1167.0 1168.0
% change (MC/SC) +10.6 +10.4 +1.5  0.2  18.5  11.8  24.4 +23.9
p-Value* 0.005 0.003 0.084 0.433 0.008 0.006 0.023 0.002
MC, multi-channel applicator; SC, single-channel applicator.
*Using Wilcoxon signed rank sum test.
One Syed plan was created for each treated patient to simulate
a single interstitial insertion used according to our institutional
practice. We measured dose to the tumor and vagina, but did not
measure dose to the OARs (bladder and rectum) as we would
avoid inserting interstitial needles into these surrounding organs.
A Wilcoxon signed rank sum test for non-parametric data was
used to compare various dosimetric points of MC versus SC,
and MC versus Syed, with significance assessed at a p< 0.05.
All statistical analyses were performed using SPSS version 21
(SPSS Inc., Chicago, IL, USA). Following treatment with MC, all
patients were evaluated for tumor response and bladder, rectal,
and vaginal toxicity assessed with the radiation therapy oncology
group (RTOG) acute and late radiation morbidity scoring system.
This retrospective study was approved by the institutional review
board.
Results
A total of 28 plans, including 12 MC plans, 12 SC plans, and 4
Syed plans were generated in this study. The treated length along
the MC measured an average of 6.6 cm (range, 5.7–7.9 cm) and
the average number of loaded catheters used in each optimized
plan was 11 (range, 9–13 catheters). The applicator was inflated
with saline to a median volume of 72.5 cm3 (range, 45–87 cm3).
Unlike a fixed diameter rigid SC, the diameter of the MC varied
according to the patient’s pelvic anatomy. The average diameter
10mm from apex of the MC and the maximum diameter of
the MC measured 36.0mm (range, 27.6–42.0mm) and 44.0mm
(range, 33.1–50.0mm), respectively. Median planning time, from
completion of CT simulation with MC in place to completion
of plan, was 140.5min (range, 73–188min). Median time for
MC procedure from simulation to removal of applicator was 3 h.
Patients who had discomfort with bladder distention were given
narcotic medications. All patients were treated without a foley
catheter and underwent MC treatment with a full bladder.
The PTV700 cGy for the 12 MC plans measured an aver-
age volume of 2.0 cm3 (range, 1.6–3.1 cm3) at an average depth
of 9.0mm (range, 7.0–9.7mm) from the vaginal surface. Target
coverage for patients treated with the MC was optimized to a
mean D99 and D95 of 711.6 cGy (range, 679.5–747.6 cGy) and
749.3 cGy (range, 722.0–782.2 cGy), respectively. In addition to
targeting PTV700 cGy with a SIB to a planned dose of 700 cGy,
the upper vagina was treated to a planned dose of 500 cGy at 5mm
depth. The mean D99 and D95 to the upper vagina (PTV500
cGy) were 484.0 cGy (range, 400.7–561.7 cGy) and 523.3 cGy
(range, 472.9–610.8 cGy), respectively. The mean D2cm3 to blad-
der and rectum were 576.4 cGy (range, 407.4–717.8 cGy) and
TABLE 2 | Comparison of dosimetry to target (PTV) between multi-channel
applicator and Syed.
PTV700
cGy
D99 (cGy)
PTV700
cGy
D95 (cGy)
PTV500
cGy
D99 (cGy)
PTV500
cGy
D95 (cGy)
MC 711.6 743.9 484.0 523.3
Syed 717.0 739.2 486.8 539.9
% change (MC/Syed)  0.8 0.6  0.6  3.1
p-Value* 0.273 0.715 0.715 0.068
MC, multi-channel applicator.
*Using Wilcoxon signed rank sum test.
622.8 cGy (range, 548.1–713.5 cGy), the mean ipsilateral vaginal
mucosa point dose within PTV700 cGy was 1448.2 cGy (range,
941.8–2137.8 cGy), while the mean contralateral vaginal mucosa
point dose contralateral to PTV700 cGy was 882.0 cGy (range,
659.7–1384.7 cGy). The median maximum cumulative BED3 to
the proximal vaginal mucosa in the area of tumor was 131.8
Gy3 (range, 119.5–136.7 Gy3), and median maximum cumu-
lative EQD2 Gy3 to the proximal vaginal mucosa in the area
of tumor was 206.6Gy (range, 151.8–237.9Gy). Contralateral
median cumulative dose to vaginal mucosa was 107.7 Gy3 (range,
104.8–109.0 Gy3), corresponding to a median cumulative EQD2
of 64.6Gy (range, 62.9–65.4Gy).
Modeling of 12 SC plans was created by setting the D95 of
PTV500 cGy equivalent between the 12 MC and 12 SC plans.
Mean D99 and D95 of PTV700 cGy were 643.2 cGy (range,
486.68–682.47 cGy) and 674.1 cGy (range, 475.37–706.43 cGy),
respectively. There was a 10.6 and 11.2% decrease in tumor cov-
erage, respectively, compared to MC plans. Improvement in dose
coverage of PTV700 cGy was statistically significant (p< 0.05) in
favor of the MC plans compared to the SC plans. Mean ipsilat-
eral vaginal mucosa point dose in the SC plans was 1167.7 cGy
(range, 910.9–1428.9 cGy). Mean D2cm3 to bladder, rectum, and
contralateral vaginal mucosal point dose were 707.1 cGy (range,
536.52–1005.33Gy), 706.0 cGy (range, 638.97–746.3 cGy), and
1166.9 cGy (range, 935.3–1404.0 cGy), respectively, with a 22.7,
13.4, and a 32.3% increase in dose, respectively, when compared
to MC plans (Table 1). Decreased dose to surrounding OARs was
statistically significant (p< 0.05) in favor of MC compared to SC
plans.
Modeling of four Syed plans were also performed by maintain-
ing equivalence between the D95 of PTV500 cGy between four
MCand four Syed plans.Optimization required use of 15 catheters
for each modeled Syed plan. Syed mean D99 and D95 of PTV700
cGywas 717.0 cGy (range, 699.0–747.4 cGy) and 739.2 cGy (range,
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TABLE 3 | Dosimetry to target (PTV) and OARs in example patient shown in Figure 3 using multi-channel applicator, single-channel applicator, and Syed.
PTV 700
cGy D99
PTV 700
cGy D95
PTV 500
cGy D99
PTV 500
cGy D95
D2cc bladder
(cGy)
D2cc rectum
(cGy)
Contralateral
mucosa (cGy)
Ipsilateral
mucosa (cGy)
MC
Insertion 1 720.2 743.6 469.8 497.0 644.2 635.7 1057.6 1478.3
Insertion 2 739.4 782.2 461.2 502.8 550.9 587.7 721.2 2137.8
Insertion 3 731.3 761.1 488.8 516.7 623.9 569.8 683.2 1235.2
SC
Insertion 1 637.0 656.6 466.6 498.2 743.3 694.6 1077.5 1258.6
Insertion 2 677.0 709.5 459.3 500.5 692.0 694.2 1058.7 1400.5
Insertion 3 677.9 704.2 465.2 515.1 729.4 825.4 1298.7 1144.7
Syed
Insertion 1 692.2 716.4 419.7 531.0 N/A N/A N/A N/A
MC, multi-channel applicator; SC, single-channel applicator; N/A, not applicable.
716.4–774.3 cGy), with a 0.8% increase and 1.3% decrease in dose,
respectively, when compared to MC plans (Table 2). However,
tumor coverage (PTV700 cGy) was not statistically significant
when comparing the Syed to MC plans. An example of the range
of dosimetric values for a patient plannedwith aMC, SC, and Syed
is shown in Table 3.
At a median follow-up of 17.3months (range, 12.4–
18.2months), one patient presented with grade 2 gastrointestinal
toxicity (rectal bleeding without medical intervention) which has
since resolved at her most recent follow-up at 16.7months, one
presented with grade 2 vaginal toxicity (ecchymosis in the vaginal
mucosa) at 12.4months, and another presented with grade 1
vaginal toxicity at most recent follow-up at 18.2months. Toxicity
was minimal overall at each patient’s most recent follow-up
(Table 4). In addition, there was no evidence of vaginal disease
on pelvic examination or pelvic disease on imaging in all four
patients treated with whole pelvis radiation followed by treatment
with MC.
Discussion
We demonstrated that use of a MC such as the Capri™ provides
superior dosimetric coverage of tumor volume with lower dose
to surrounding normal tissues compared to a SC in the four cases
studied. The results of this study, an 18.5 and 11.8% absolute
reduction in the bladder and rectum D2cm3, are consistent with
other series demonstrating a reduction in the bladder and rectum
dose, in favor of a MC compared to a SC (13). In addition, MC
provides comparable dosimetric coverage versus a Syed implant
for vaginal tumors >5mm but 10mm in depth. Although a
prior study has compared SC to MC, this dosimetric comparison
between a MC and Syed has to our knowledge not been studied
until now.
A potential criticism of this study is that all SC and Syed
plans were generated using the patient’s MC-based CT data set.
Although our study compared a MC with a SC, all SC plans were
modeled with the patient’s existing MC CT data. As a result, the
modeled SC cylinder diameter is larger than one would expect in
a clinical setting where a rigid SC cylinder is used. This is due to
intrinsic properties of the MC, as the diameter can be increased
asymmetrically to sizes greater than is commercially available with
SC. Although comparison of aMC to a SCwas derived using aMC
image data set, these results should translate to a situation using
TABLE 4 | Record of toxicity following treatment with whole pelvis radiation
and multi-channel applicator treatment using the RTOG Late Radiation
Morbidity Scoring Schema.
Patient Follow-up
(months)
Gastrointestinal
toxicity
Bladder
toxicity
Vaginal
toxicity
1 12.4 None None Grade 2
2 18.2 None None Grade 1
3 16.7 Grade 2a None None
4 17.8 None None None
aGrade 2 rectal bleeding noted at 1 year completely resolved at 1.5 years follow-up.
a CT-set with a rigid SC in place and would represent the best
case scenario for the SC configuration. Future studies may include
simulating patients with both a MC and a rigid SC cylinder to
better compare differences in dosimetry with respect to the target
volume and OARs.
Due to the increased complexity and longer planning time
(median 140.5min) using the Capri™ device compared to using a
SC, a potential tradeoff using this device may be underdosing the
tumor volume or exaggeration of themagnitude in dose reduction
to OARs. However, re-planning prior to delivery of each fraction
and use of fiducial markers in the area of the target volume were
strategies used to help offset these potential errors. Increased
familiarity and creating a streamlined approach using this device
may further decrease any potential intra or interfractional
errors.
Patients with vaginal tumors>10mm in depth following whole
pelvis radiation were not included in this study due to concerns
of unacceptably high risks of toxicity to surrounding normal
tissue including vagina, bladder, and rectum. Patients with vaginal
tumors located in the apex of the vaginal cuffmay lead to increased
dose to overlying sigmoid colon or bowel when treated with MC
prescribing to deeper coverage for tumors in this location. Both
clinical situations involving deeper (>10mm) or apical tumors
may best be addressed using an interstitial implant with laparo-
scopic displacement of bowel if necessary.
Although it was possible to load fewer than 13 catheters when
treating patients in this study, an increased number of catheters
allowed flexibility in plan optimization with improved tumor
coverage while reducing risk of treatment-relatedmorbidity to the
bladder, rectum, and vagina. The optimal number of catheters
to use in a patient is highly dependent on a number of factors,
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including tumor location, depth of tumor, pelvic anatomy, and the
ability to deliver a SIB.
Clinically, the Capri™ was rigidly secure in the patient after
saline filling, demonstrating reliable positioning in the rotational
and transverse planes. As shown in Figure 1, the apical yellow
catheter demarcates zero degrees ensuring accurate placement and
the central catheter was marked ensuring that the device was not
slipping out of the patient. After planning, MC device position-
ing was clinically confirmed prior to proceeding with treatment.
Replanning therefore was not deemed necessary. However, future
evaluation may be performed to evaluate intrafraction variability.
Our patients were treated with a SIB approach to the PTV700
cGy demarcated by clips which depending on device placement
could vary in position; therefore, we felt that replanning was
necessary to be performed prior to each fraction delivered. SIB
treatment allowed for contralateral vaginal mucosa sparing that
may reduce long-term vaginal toxicity. In addition, our median
cumulative proximal vaginal mucosal dose (EQD2) was within
the reported threshold (EQD2 of 238Gy) for proximal vaginal
necrosis (17), with no events >grade 2 vaginal toxicity reported
in our cohort.
Replanning with the Capri™ device may not be necessary in
the interfraction setting if one utilizes uniform dose prescription
to the vaginal target. As demonstrated by a dosimetric study,
replanning was not necessary prior to each fraction using SC or
MC vaginal cylinders with respect to OAR (18).
Despite these limitations, a MC such as the Capri™ can serve as
a viable non-invasive treatmentmodality alternative to an intersti-
tial implant for patients with vaginal tumors up to 10mm in depth
with preferred dosimetry, compared to SC which would produce
unacceptably high normal tissue doses. At a median follow-up
of 17.3months, all patients treated with the MC presented with
no evidence of tumor recurrence on pelvic exam with minimal
treatment-related toxicity. Furthermore, use of a MC under these
conditions can result in significant cost savings, more rapid recov-
ery time and is a less invasive procedure compared to a traditional
Syed applicator (10, 19–21). However, a larger cohort of patients
and continued follow-up of treated patients are required to assess
long-term clinical outcomes, including disease control and tissue
toxicity using this technical approach.
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